Physician profile
Bruce Mitchell Yergin
NPI 1619962230
$1,924.15
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $301 · 2021: $22.39 · 2022: $29.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $625.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $317.68 | 2019-2020 | |
| Genzyme Corporation | $193.03 | 2019-2020 | |
| Grifols USA, LLC | $186.05 | 2019-2020 | |
| Philips North America LLC | $170.61 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.21 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $90.23 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $61.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $46.13 | 2019 | |
| Electromed, INC. | $44.39 | 2019 | |
| Genentech USA, INC. | $35.33 | 2019 | |
| Portola Pharmaceuticals, LLC | $12.87 | 2019 | |
| Circassia INC. | $12.62 | 2019 | |
| Shire North American Group INC | $12.21 | 2019 | |
| Ethicon INC. | $11.39 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Yergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.